全文获取类型
收费全文 | 46361篇 |
免费 | 5679篇 |
国内免费 | 878篇 |
专业分类
耳鼻咽喉 | 160篇 |
儿科学 | 1462篇 |
妇产科学 | 1034篇 |
基础医学 | 2657篇 |
口腔科学 | 1206篇 |
临床医学 | 5688篇 |
内科学 | 9939篇 |
皮肤病学 | 436篇 |
神经病学 | 2992篇 |
特种医学 | 801篇 |
外国民族医学 | 1篇 |
外科学 | 4587篇 |
综合类 | 4375篇 |
现状与发展 | 8篇 |
一般理论 | 9篇 |
预防医学 | 9406篇 |
眼科学 | 642篇 |
药学 | 3369篇 |
26篇 | |
中国医学 | 359篇 |
肿瘤学 | 3761篇 |
出版年
2024年 | 173篇 |
2023年 | 1234篇 |
2022年 | 2035篇 |
2021年 | 2939篇 |
2020年 | 2745篇 |
2019年 | 2513篇 |
2018年 | 2459篇 |
2017年 | 2292篇 |
2016年 | 2276篇 |
2015年 | 2090篇 |
2014年 | 3577篇 |
2013年 | 4297篇 |
2012年 | 2622篇 |
2011年 | 2833篇 |
2010年 | 2140篇 |
2009年 | 2061篇 |
2008年 | 2098篇 |
2007年 | 1866篇 |
2006年 | 1641篇 |
2005年 | 1444篇 |
2004年 | 1159篇 |
2003年 | 967篇 |
2002年 | 841篇 |
2001年 | 759篇 |
2000年 | 576篇 |
1999年 | 465篇 |
1998年 | 411篇 |
1997年 | 352篇 |
1996年 | 266篇 |
1995年 | 265篇 |
1994年 | 215篇 |
1993年 | 221篇 |
1992年 | 169篇 |
1991年 | 141篇 |
1990年 | 115篇 |
1989年 | 102篇 |
1988年 | 93篇 |
1987年 | 76篇 |
1986年 | 58篇 |
1985年 | 84篇 |
1984年 | 67篇 |
1983年 | 33篇 |
1982年 | 46篇 |
1981年 | 27篇 |
1980年 | 23篇 |
1979年 | 14篇 |
1978年 | 8篇 |
1977年 | 10篇 |
1976年 | 7篇 |
1972年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
992.
Robert S. Gaston Vineeta Kumar Arthur J. Matas 《Journal of the American Society of Nephrology : JASN》2015,26(5):1017-1019
The short- and long-term effects of unilateral nephrectomy on living donors have been important considerations for 60 years. Short-term risk is well established (0.03% mortality and <1% risk of major morbidity), but characterization of long-term risk is evolving. Relative to the general population, risk of mortality, ESRD, hypertension, proteinuria, and cardiovascular disease is comparable or lower. However, new studies comparing previous donors with equally healthy controls indicate increased risk of metabolic derangements (particularly involving calcium homeostasis), renal failure, and possibly, mortality. We discuss how these results should be interpreted and their influence on the practice of living donor kidney transplantation. 相似文献
993.
John Kalbfleisch Robert Wolfe Sarah Bell Rena Sun Joseph Messana Tempie Shearon Valarie Ashby Robin Padilla Min Zhang Marc Turenne Jeffrey Pearson Claudia Dahlerus Yi Li 《Journal of the American Society of Nephrology : JASN》2015,26(11):2641-2645
Standardized mortality ratios (SMRs) reported by Medicare compare mortality at individual dialysis facilities with the national average, and are currently adjusted for race. However, whether the adjustment for race obscures or clarifies disparities in quality of care for minority groups is unknown. Cox model-based SMRs were computed with and without adjustment for patient race for 5920 facilities in the United States during 2010. The study population included virtually all patients treated with dialysis during this period. Without race adjustment, facilities with higher proportions of black patients had better survival outcomes; facilities with the highest percentage of black patients (top 10%) had overall mortality rates approximately 7% lower than expected. After adjusting for within-facility racial differences, facilities with higher proportions of black patients had poorer survival outcomes among black and non-black patients; facilities with the highest percentage of black patients (top 10%) had mortality rates approximately 6% worse than expected. In conclusion, accounting for within-facility racial differences in the computation of SMR helps to clarify disparities in quality of health care among patients with ESRD. The adjustment that accommodates within-facility comparisons is key, because it could also clarify relationships between patient characteristics and health care provider outcomes in other settings. 相似文献
994.
Marcus E. Kleber Graciela Delgado Tanja B. Grammer Günther Silbernagel Jie Huang Bernhard K. Kr?mer Eberhard Ritz Winfried M?rz 《Journal of the American Society of Nephrology : JASN》2015,26(11):2831-2838
Obesity and diets rich in uric acid–raising components appear to account for the increased prevalence of hyperuricemia in Westernized populations. Prevalence rates of hypertension, diabetes mellitus, CKD, and cardiovascular disease are also increasing. We used Mendelian randomization to examine whether uric acid is an independent and causal cardiovascular risk factor. Serum uric acid was measured in 3315 patients of the Ludwigshafen Risk and Cardiovascular Health Study. We calculated a weighted genetic risk score (GRS) for uric acid concentration based on eight uric acid–regulating single nucleotide polymorphisms. Causal odds ratios and causal hazard ratios (HRs) were calculated using a two-stage regression estimate with the GRS as the instrumental variable to examine associations with cardiometabolic phenotypes (cross-sectional) and mortality (prospectively) by logistic regression and Cox regression, respectively. Our GRS was not consistently associated with any biochemical marker except for uric acid, arguing against pleiotropy. Uric acid was associated with a range of prevalent diseases, including coronary artery disease. Uric acid and the GRS were both associated with cardiovascular death and sudden cardiac death. In a multivariate model adjusted for factors including medication, causal HRs corresponding to each 1-mg/dl increase in genetically predicted uric acid concentration were significant for cardiovascular death (HR, 1.77; 95% confidence interval, 1.12 to 2.81) and sudden cardiac death (HR, 2.41; 95% confidence interval, 1.16 to 5.00). These results suggest that high uric acid is causally related to adverse cardiovascular outcomes, especially sudden cardiac death. 相似文献
995.
Giorgina Barbara Piccoli Gianfranca Cabiddu Rossella Attini Federica Neve Vigotti Stefania Maxia Nicola Lepori Milena Tuveri Marco Massidda Cecilia Marchi Silvia Mura Alessandra Coscia Marilisa Biolcati Pietro Gaglioti Michele Nichelatti Luciana Pibiri Giuseppe Chessa Antonello Pani Tullia Todros 《Journal of the American Society of Nephrology : JASN》2015,26(8):2011-2022
CKD is increasingly prevalent in pregnancy. In the Torino-Cagliari Observational Study (TOCOS), we assessed whether the risk for adverse pregnancy outcomes is associated with CKD by comparing pregnancy outcomes of 504 pregnancies in women with CKD to outcomes of 836 low-risk pregnancies in women without CKD. The presence of hypertension, proteinuria (>1 g/d), systemic disease, and CKD stage (at referral) were assessed at baseline. The following outcomes were studied: cesarean section, preterm delivery, and early preterm delivery; small for gestational age (SGA); need for neonatal intensive care unit (NICU); new onset of hypertension; new onset/doubling of proteinuria; CKD stage shift; “general” combined outcome (preterm delivery, NICU, SGA); and “severe” combined outcome (early preterm delivery, NICU, SGA). The risk for adverse outcomes increased across stages (for stage 1 versus stages 4–5: “general” combined outcome, 34.1% versus 90.0%; “severe” combined outcome, 21.4% versus 80.0%; P<0.001). In women with stage 1 CKD, preterm delivery was associated with baseline hypertension (odds ratio [OR], 3.42; 95% confidence interval [95% CI], 1.87 to 6.21), systemic disease (OR, 3.13; 95% CI, 1.51 to 6.50), and proteinuria (OR, 3.69; 95% CI, 1.63 to 8.36). However, stage 1 CKD remained associated with adverse pregnancy outcomes (general combined outcome) in women without baseline hypertension, proteinuria, or systemic disease (OR, 1.88; 95% CI, 1.27 to 2.79). The risk of intrauterine death did not differ between patients and controls. Findings from this prospective study suggest a “baseline risk” for adverse pregnancy-related outcomes linked to CKD. 相似文献
996.
Deirdre Sawinski Kimberly A. Forde Jennifer Trofe-Clark Priyanka Patel Beatriz Olivera Simin Goral Roy D. Bloom 《Journal of the American Society of Nephrology : JASN》2015,26(4):966-975
There are limited data regarding intermediate-term outcomes in patients with persistent BK viremia. Other viral infections have been implicated in the development of allosensitization through heterologous immunity, but the relationship between BK viremia and donor-specific antibodies (DSAs) is unexplored. In 2008, we initiated routine post-transplant BK viremia and DSA screening at our center; 785 kidney or kidney–pancreas transplant recipients were included in our study. Of these recipients, 132 (17%) recipients developed BK viremia during the study period. The median duration of BK viremia was 140 days (interquartile range=40–393 days), and persistent BK viremia was defined as lasting ≥140 days. Kaplan–Meier curves were generated to assess differences in patient and allograft survival on the basis of BK viremia status; survival was modeled using Cox proportional hazard regression. After a median follow-up of 3 years, there was no significant difference in terms of patient (hazard ratio [HR], 0.83; 95% confidence interval [95% CI], 0.28 to 2.49) or allograft survival (HR, 0.80; 95% CI, 0.37 to 1.73) between patients with and without BK viremia, which was confirmed in a time-varying analysis. In our logistic regression model, persistent BK viremia was strongly associated with the development of class II (HR, 2.55; 95% CI, 1.30 to 4.98) but not class I (HR, 1.13; 95% CI, 0.46 to 2.77) DSAs. These data suggest that persistent BK viremia does not negatively affect intermediate-term patient or allograft survival but is associated with increased risk for de novo DSA, although the exact mechanism is unclear. 相似文献
997.
998.
Interferon Gamma ELISPOT Testing as a Risk‐Stratifying Biomarker for Kidney Transplant Injury: Results From the CTOT‐01 Multicenter Study 下载免费PDF全文
D. E. Hricik J. Augustine P. Nickerson R. N. Formica E. D. Poggio D. Rush K. A. Newell J. Goebel I. W. Gibson R. L. Fairchild K. Spain D. Iklé N. D. Bridges P. S. Heeger for the CTOT‐ consortium 《American journal of transplantation》2015,15(12):3166-3173
Previous studies suggest that quantifying donor‐reactive memory T cells prior to kidney transplantation by interferon gamma enzyme‐linked immunosorbent spot assay (IFNγELISPOT) can assist in assessing risk of posttransplant allograft injury. Herein, we report an analysis of IFNγELISPOT results from the multicenter, Clinical Trials in Organ Transplantation‐01 observational study of primary kidney transplant recipients treated with heterogeneous immunosuppression. Within the subset of 176 subjects with available IFNγELISPOT results, pretransplant IFNγELISPOT positivity surprisingly did not correlate with either the incidence of acute rejection (AR) or estimated glomerular filtration rate (eGFR) at 6‐ or 12‐month. These unanticipated results prompted us to examine potential effect modifiers, including the use of T cell‐depleting, rabbit anti‐thymocyte globulin (ATG). Within the no‐ATG subset, IFNγELISPOTneg subjects had higher 6‐ and 12‐month eGFRs than IFNγELISPOTpos subjects, independent of biopsy‐proven AR, peak PRA, human leukocyte antigen mismatches, African‐American race, donor source, and recipient age or gender. In contrast, IFNγELISPOT status did not correlate with posttransplant eGFR in subjects given ATG. Our data confirm an association between pretransplant IFNγELISPOT positivity and lower posttransplant eGFR, but only in patients who do not receive ATG induction. Controlled studies are needed to test the hypothesis that ATG induction is preferentially beneficial to transplant candidates with high frequencies of donor‐reactive memory T cells. 相似文献
999.
Superior Sensitivity of Ex Vivo IFN‐γ Release Assays as Compared to Skin Testing in Immunocompromised Patients 下载免费PDF全文
T. Scholman M. Straub G. Sotgiu J. Elsäßer S. Leyking M. Singh U. Sester D. Wagner M. Sester 《American journal of transplantation》2015,15(10):2616-2624
Comparative assessment of the tuberculin skin testing (TST) and commercial IFN‐γ release‐assays (IGRAs) is hampered by the use of different antigens (tuberculin PPD in TST vs. ESAT‐6/CFP‐10 in IGRAs). Thus, PPD was used as a common stimulus to compare performance of the TST and three IGRAs in 72 controls, 101 hemodialysis patients and 100 renal transplant recipients. Results of the TST were compared with PPD‐induced IFN‐γ induction in vitro detected by ELISPOT, ELISA or a flow‐cytometric FACS assay. Percentages of positive tests were significantly lower in TST (9.2%) compared to ELISA (55.3%), ELISPOT (45.3%) and FACS (44.9%, p < 0.0001). Agreement between TST and IGRAs was highest for controls (κ = 0.19–0.32) and poor in immunocompromised patients (κ = 0 for transplant patients, κ = 0.06–0.13 for hemodialysis patients). Discrepant results were largely TST negative and IGRA positive. Among IGRAs, agreement was highest between ELISPOT and FACS (κ = 0.61). Unlike TST, all IGRAs were associated with variables of mycobacterial exposure. Among IGRAs, the FACS assay was least affected by the level of immunosuppression. In conclusion, both the percentage of positive results and between‐test‐agreement were higher with IGRAs as compared to TST. This indicates superiority of IGRAs in detecting a PPD‐specific immune response which may also apply for immunity toward Mycobacterium tuberculosis–specific antigens. 相似文献
1000.
目的 探讨常规血液透析和高通量血液透析两种不同治疗方式对维持性血液透析患者微炎症状态和营养状况的影响.方法 选取50例维持性血液透析患者随机分成常规透析(CHD)和高通量透析(HFHD)两组,分别测定两组患者入组后首次透析(透析前)和治疗3个月后(透析前)的血浆白蛋白(Alb)、血清C反应蛋白(CRP)、白细胞介素-6(IL-6)的水平进行比较,同时比较治疗前后体重指数、肱三头肌皮肤皱褶厚度(TSF)、上臂围(MAC)和上臂肌围(MAMC)的变化.结果 CHD组治疗3个月后对IL-6、CRP清除差异无统计学意义(P>0.05),对Alb的影响差异无统计学意义(P>0.05);HFHD组治疗3个月后对IL-6、CRP清除差异有统计学意义(P<0.05),对Alb的提升差异有统计学意义(P<0.05);HFHD组治疗3个月后TSF、MAC测量值升高,但是差异无统计学意义(P>0.05),两组治疗后对BMI、MAMC的测量值差异无统计学意义.结论 高通量透析与常规透析相比对IL-6和CRP等微炎症细胞因子的清除能力更显著,对改善微炎症状态有积极作用;且与常规透析相比对营养状态的改善也有一定帮助作用. 相似文献